St. Jude Halts FAME II Enrollment
Medical devices major St. Jude Medical (NYSE:STJ - News) will stop enrolling new patients in its FAME II clinical trial following positive results from an interim analysis. The independent data safety monitoring board (“DSMB”) recommended investigators to halt patient enrollment in the study following the impressive results which have shown statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve (“FFR”)-guided assessment
Read Full Article
Login to comment.